Biotech Stocks Weekly Roundup

biotech_industry_08-512x384

PRevious Few Days have been very eventful for the Biotech Stocks. Last week, earnings remained in focus with several companies reporting their second quarter results. While Amgen’s (AMGN) results remained impressive, Vertex (VRTX) posted a wider loss. Meanwhile, Regeneron (REGN) missed earnings expectations by a pretty wide margin though Eylea sales continued to impress.

Among all this, the Ebola outbreak is also making headlines and has brought quite a few biotech companies into the limelight for their experimental Ebola disease treatments. One of the companies involved in the development of an anti-Ebola virus treatment is Canada-based Tekmira (TKMR). Although Tekmira’s phase I candidate, TKM-Ebola is currently under clinical hold, hopes are up that an early resolution of the hold could materialize given the urgent need for Ebola virus treatments

Vertex reported a wider loss in the second quarter with revenues also lagging expectations. Shares were down on the earnings report. The company maintained its outlook for 2014. Cystic fibrosis treatment, Kalydeco, should benefit from the recent approval of eight additional mutations in the EU – this provides access to 250 eligible patients.

Biotech Stock News

Amgen was in the news not just for its impressive second quarter performance but also for its decision to implement a restructuring plan and cut 2,400-2,900 positions (12% – 15% of the total work force). Investors viewed the company’s restructuring plan favorably with shares gaining 5.4%- the restructuring plan should make the company leaner and more cost-efficient.

Regeneron’s second quarter earnings missed expectations by a wide margin. Revenues, however, surpassed expectations with eye drug, Eylea, performing well in the quarter. Eylea should see accelerated growth in the second half of the year thanks to the recent FDA approval for diabetic macular edema (DME). The drug could gain FDA approval for a fourth indication – macular edema following branch retinal vein occlusion – in October. The company is also preparing to file for approval of its PCSK9 inhibitor, alirocumab.

Biotech News Video

Watch this video for more “Biotech” news.

Biotech Financial News

Although second quarter earnings season is almost coming to an end, some Biotech companies are yet to report results. Later this week, companies like Medivation (MDVN) and Auxilium (AUXL) will be reporting. Meanwhile, The Medicines Co. (MDCO) has an important regulatory event coming up with the FDA expected to respond on the approval status of antibiotic candidate, Orbactiv.

Thanks for visiting the TechNews.org website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone